Cerapedics completed a US $11MM Series D financing. Funds will support expanded commercialization of i-FACTOR™ Peptide Enhanced Bone Graft, which received FDA premarket approval in 4Q15 for use in anterior cervical discectomy and fusion (ACDF) to treat degenerative disc disease. Proceeds will also further development of synthetic small peptide technology (P-15) for lumbar spinal fusion.
The 4Q15 PMA for i-FACTOR represented the first approval of bone graft for use in the cervical spine, and the second PMA-approved bone graft in the spine (the first being INFUSE).
Cerapedics completed a US $11MM Series D financing. Funds will support expanded commercialization of i-FACTOR™ Peptide Enhanced Bone Graft, which received FDA premarket approval in 4Q15 for use in anterior cervical discectomy and fusion (ACDF) to treat degenerative disc disease. Proceeds will also further development of synthetic small peptide...
Cerapedics completed a US $11MM Series D financing. Funds will support expanded commercialization of i-FACTOR™ Peptide Enhanced Bone Graft, which received FDA premarket approval in 4Q15 for use in anterior cervical discectomy and fusion (ACDF) to treat degenerative disc disease. Proceeds will also further development of synthetic small peptide technology (P-15) for lumbar spinal fusion.
The 4Q15 PMA for i-FACTOR represented the first approval of bone graft for use in the cervical spine, and the second PMA-approved bone graft in the spine (the first being INFUSE).
Copy to clipboard 
